The burgeoning popularity of tirzepatide , initially for blood sugar control , is creating significant buzz within the UK , prompting a notable shift in hormone trends. Access these compounds remains a complex challenge , with public healthcare system provision currently limited and specialist practices offering therapy at a higher cost . Worries a